ストックスクリーナーアプリを入手
4.10
5.31%
-0.23
アフターアワーズ：
4.06
-0.04
-0.98%
前日終値:
$4.33
開ける：
$4.33
24時間の取引高:
88,923
Relative Volume:
1.06
時価総額：
$43.31M
収益：
$1.93M
当期純損益:
$-7.96M
株価収益率:
-0.00116
EPS:
-3530.8178
ネットキャッシュフロー:
$-36.78M
1週間 パフォーマンス:
+2.50%
1か月 パフォーマンス:
-14.23%
6か月 パフォーマンス:
-59.61%
1年 パフォーマンス:
-62.69%
1日の値動き範囲:
$4.06
$4.49
1週間の範囲:
$3.93
$4.71
52週間の値動き範囲:
$3.39
$16.00
Avalo Therapeutics Inc Stock (AVTX) Company Profile
AVTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
4.10 | 43.31M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | 再開されました | H.C. Wainwright | Buy |
| 2025-03-25 | 開始されました | Jefferies | Buy |
| 2025-03-25 | 開始されました | Stifel | Buy |
| 2025-02-28 | 開始されました | Piper Sandler | Overweight |
| 2025-02-21 | 開始されました | Wedbush | Outperform |
| 2024-12-19 | 開始されました | BTIG Research | Buy |
| 2024-10-24 | 開始されました | H.C. Wainwright | Neutral |
| 2024-04-16 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-09-24 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Avalo Therapeutics Inc (AVTX) 最新ニュース
Avalo Therapeutics Signs New Sales Agreement - TipRanks
Avalo Therapeutics Highlights AVTX-009 Potential in HS Market - TipRanks
Northern Trust Corp Invests $168,000 in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Upgraded at HC Wainwright - Defense World
H.C. Wainwright upgrades Avalo Therapeutics stock to buy - Investing.com
Avalo Therapeutics assumed with a Buy at H.C. Wainwright - TipRanks
H.C. Wainwright upgrades Avalo Therapeutics stock to buy By Investing.com - Investing.com South Africa
AVTX: Avalo Therapeutics Receives Buy Rating with $15 Target Pri - GuruFocus
Avalo Therapeutics (AVTX) Receives Buy Rating from H.C. Wainwright | AVTX Stock News - GuruFocus
Cardax (OTCMKTS:CDXI) and Avalo Therapeutics (NASDAQ:AVTX) Head-To-Head Analysis - Defense World
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update - Defense World
Avalo Therapeutics to Participate in Upcoming Investor Conferenc - GuruFocus
Avalo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $33.00 - Defense World
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Shares Bought by Tower Research Capital LLC TRC - Defense World
Strong Cash Position Secures AVTX Through 2027 | AVTX Stock News - GuruFocus
Avalo Therapeutics Reports Improved Financial Performance - TipRanks
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates - GlobeNewswire
Avalo Therapeutics reports Q1 EPS ($1.25) vs. ($141.14) last year - TipRanks
Avalo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
AVTX Advances Phase 2 LOTUS Trial, Targets 2026 Data | AVTX Stoc - GuruFocus
AVALO THERAPEUTICS Earnings Results: $AVTX Reports Quarterly Earnings - Nasdaq
Avalo Reports First Quarter 2025 Financial Results and Recent Bu - GuruFocus
Avalo Therapeutics Announces Leadership Change and Updates on AVTX-009 Phase 2 Trial for Hidradenitis Suppurativa - Nasdaq
Avalo Therapeutics, Inc. SEC 10-Q Report - TradingView
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates - GlobeNewswire Inc.
Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Monday - Defense World
Avalo Therapeutics Updates on AVTX-009 and LOTUS Trial - TipRanks
15,323 Shares in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Acquired by Marshall Wace LLP - Defense World
When the Price of (AVTX) Talks, People Listen - news.stocktradersdaily.com
Avalo Therapeutics Enters $75 Million Sales Agreement With TD Cowen For Common Stock Offering - marketscreener.com
Geode Capital Management LLC Increases Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference - The Manila Times
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Up 20.3% in March - Defense World
60,000 Shares in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Purchased by Bank of Montreal Can - Defense World
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $33.00 Average PT from Brokerages - Defense World
Avalo Therapeutics (AVTX) Sees New Options Listings for April | AVTX Stock News - GuruFocus
Seven new option listings and one option delisting on April 16th - TipRanks
Avalo Therapeutics Reports 2024 Financial Results - TipRanks
Advanced Cancer Pain Management Therapeutics Market Size in 7MM - openPR.com
(AVTX) On The My Stocks Page - news.stocktradersdaily.com
AVTX stock touches 52-week low at $5.98 amid market challenges - Investing.com Australia
AVTX stock touches 52-week low at $5.98 amid market challenges By Investing.com - Investing.com South Africa
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at Stifel Nicolaus - MarketBeat
Avalo Therapeutics (AVTX) to Release Earnings on Friday - Defense World
Analysts Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $33.00 - Defense World
Avalo Therapeutics names new Chairman amid growth phase By Investing.com - Investing.com South Africa
Avalo Therapeutics Names Michael Heffernan as Board Chairman - MarketScreener
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board - GlobeNewswire
Avalo Therapeutics Appoints Michael Heffernan As Chairman Of The Board - MarketScreener
Avalo Therapeutics Inc (AVTX) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):